A multi-centre, post-marketing surveillance study of Vi polysaccharide–tetanus toxoid conjugate vaccine (Typbar TCV®) in India

References

• Mogasale V, Maskery B, OchiaiR L, LeeJ S, MogasaleV V, Ramani E, Kim YE, Park JK, Wierzba TF. Burden of typhoid fever in low-income and middle-income countries: a systematic, literature-based update with risk-factor adjustment. Lancet Glob Health. 2014;2(10):e570–7. doi:10.1016/S2214-109X(14)70301-8.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Typhoid vaccines: WHO position paper, March 2018 - recommendations. Vaccine. 2019 Jan 7;37(2):214–16. Epub 2018 Apr 13. doi:10.1016/j.vaccine.2018.04.022.
   PubMed Web of Science ®Google Scholar
• Antillon M, Warren JL, Crawford FW, Weinberger DM, Kurum E, Pak GD, Marks F, Pitzer VE. The burden of typhoid fever in low- and middle-income countries: a meta-regression approach. PLoS Negl Trop Dis. 2017;27:e0005376: 1–21.
   Google Scholar
• Waddington CS, Darton TC, Pollard AJ. The challenge of enteric fever. J Infection. 2014;68(Suppl 1):S38–50. doi:10.1016/j.jinf.2013.09.013.
   PubMed Web of Science ®Google Scholar
• Mohan VK, Varanasi V, Singh A, Pasetti MF, Levine MM, Venkatesan R, Ella KM. Safety and immunogenicity of a Vi polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV) in healthy infants, children, and adults in typhoid endemic areas: a multicenter, 2-cohort, open-label, double-blind, randomized controlled phase 3 study. Clin Infect Dis. 2015;61(3):393–402. doi:10.1093/cid/civ295.
   PubMed Web of Science ®Google Scholar
• Shakya M, Colin-Jones R, Theiss-Nyland K, Voysey M, Pant D, Smith N, Liu X, Tonks S, Mazur O, Farooq YG, et al. Phase 3 efficacy analysis of a typhoid conjugate vaccine trial in Nepal. N Engl J Med. 2019;381(23):2209–18. doi:10.1056/NEJMoa1905047.
   PubMed Web of Science ®Google Scholar
• Jin C, Gibani MM, Moore M, Juel HB, Jones E, Meiring J, Harris V, Gardner J, Nebykova A, Kerridge SA, et al. Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial. Lancet. 2017;390(10111):2472–80. doi:10.1016/S0140-6736(17)32149-9.
   PubMed Web of Science ®Google Scholar
• WHO summary of the October 2017 meeting of the strategic advisory group of experts on immunization. [accessed 2018 Nov 13]. https://www.who.int/immunization/sage/meetings/2017/october/1_Typhoid_SAGE_background_paper_Final_v3B.pdf?ua=1 .
   Google Scholar
• ICH, clinical safety data management: definitions and standards for expedited reporting E2Aa. [acccessed 2017 Nov 6]. https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E2A/Step4/E2A_Guideline.pdf .
   Google Scholar
• World Health Organization. Weekly epidemiological record; 1ST December 2017, 92TH year/No. 48. 2017. 729-748. [acccessed 2017 December]. https://www.who.int/wer/2017/wer9248/en/ .
   Google Scholar
• World Health Organization. Weekly epidemiological record; 25 JANUARY 2019, 94th YEAR/No 4, 2019, 94, 45–52. [acccessed 2019 January]. https://www.who.int/wer/2019/wer9404/en/ .
   Google Scholar
• Delage G. Rotavirus vaccine withdrawal in the United States; the role of postmarketing surveillance. Can J Infect Dis. 2000;11:10–12.
   PubMedGoogle Scholar
• Begier EM, Burwen DR, Haber P, Ball R, for the Vaccine Adverse Event Reporting System Working Group. Postmarketing safety surveillance for typhoid fever vaccines from the vaccine adverse event reporting system, July 1990 through June 2002. Clin Infect Dis. 2004;38(6):771–79. doi:10.1086/381548.
   PubMed Web of Science ®Google Scholar
• Marcus LC, Froeschle JE, Hill DR, Wolfe MS, Maus D, Connor B, Acosta AM, Rensimer ER, Roberts A, Dardick K. Safety of Typhim Vi vaccine in a postmarketing observational study. J Travel Med. 2007;14(6):386–91. doi:10.1111/j.1708-8305.2007.00158.x.
   PubMed Web of Science ®Google Scholar
• Thiem VD, Lin FYC, Canh DG, Son NH, Anh DD, Mao ND, Chu C, Hunt SW, Robbins JB, Schneerson R, et al. The Vi conjugate typhoid vaccine is safe, elicits protective levels of IgG anti-Vi, and is compatible with routine infant vaccines. Clin Vaccine Immunol. 2011;18(5):730–35. doi:10.1128/CVI.00532-10.
   PubMedGoogle Scholar
• Qamar FN, Yousafzai MT, Khaliq A, Karim S, Memon H, Junejo A, Baig I, Rahman N, Bhurgry S, Afroz H, et al. Adverse events following immunization with typhoid conjugate vaccine in an outbreak setting in Hyderabad, Pakistan. Vaccine. 2020;38(19):3518–23. doi:10.1016/j.vaccine.2020.03.028.
   PubMed Web of Science ®Google Scholar
• Lin FY, Ho VA, Khiem HB, Trach DD, Bay PV, Thanh TC, Kossaczka Z, Bryla DA, Shiloach J, RobbinsetJ B, et al. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. N Engl J Med. 2001;344(17):1263–69. doi:10.1056/NEJM200104263441701.
   PubMed Web of Science ®Google Scholar
• Kroger A, General recommendations on immunization --- recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR recommendations and reports: morbidity and mortality weekly report recommendations and reports. Atlanta (GA): National Center for Immunization and Respiratory Diseases. 2011;60:1–64. https://www.cdc.gov/mmwr/pdf/rr/rr6002.pdf .
   Google Scholar
• Parry CM, Hoa NT, Diep TS, Wain J, Chinh NT, Vinh H, Hien TT, White NJ, Farrar JJ. Value of a single-tube widal test in diagnosis of typhoid fever in Vietnam. J Clin Microbiol. 1999;37(9):2882–86. doi:10.1128/JCM.37.9.2882-2886.1999.
   PubMed Web of Science ®Google Scholar
• Sen R, Saxena SN. A critical assessment of the conventional Widal test in the diagnosis of typhoid and paratyphoid fevers. Indian J Med Res. 1969;57:1813–19.
   PubMed Web of Science ®Google Scholar
• Booy R, Heath PT, Slack MP, Begg N, Moxon ER. Vaccine failures after primary immunisation with Haemophilus influenzae type-b conjugate vaccine without booster. Lancet. 1997;349(9060):1197–202. doi:10.1016/S0140-6736(96)06392-1.
   PubMed Web of Science ®Google Scholar
• Kelly DF, Moxon ER, Pollard AJ. Haemophilus influenzae type b conjugate vaccines. Immunology. 2004 Oct;113(2):163–74.doi:10.1111/j.1365-2567.2004.01971.x.
   Google Scholar